Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

MapLight Therapeutics Q3 2026 Results: Net Loss of $51.6M, Loss Widens

MapLight Therapeutics reported a significant increase in net loss to $172.5 million for the nine months ended September 30, 2026, compared to $81.6 million in the prior year, primarily driven by a doubling of research and development expenses. The company strengthened its balance sheet through a private placement in the third quarter of 2026, yielding $140.1 million in net proceeds.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-51.6-29.4
EPS (diluted, $ a share)$-0.97$-37.18

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MPLT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

MapLight Therapeutics, Inc.: key numbers

Share price
$6.90Close, Nov 16
Market cap
$293M
Shares outstanding
42.44MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from MapLight Therapeutics, Inc.

All →
9:30 AM ET 8-K
Capital Raise

MapLight Therapeutics Capital Raise

MapLight Therapeutics entered into a sales agreement with Leerink Partners to establish an at-the-market (ATM) offering program. The company may sell up to $100 million of its common stock from time to time, with Leerink acting as the sales agent for a commission of up to 3.0%.

Counterparty
Leerink Partners LLC
7:21 AM ET 8-K
Financial Results

MapLight Therapeutics Financial Results

MapLight Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, including plans for its Phase 3 ZEPHYR-2 trial in schizophrenia. The company ended the quarter with $463.4 million in cash, which is expected to fund operations through 2028 and key clinical readouts.

Term
Q3 2026

“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market.”

Chris Kroeger, Co-Founder and Chief Executive Officer

“We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.”

Chris Kroeger, Co-Founder and Chief Executive Officer
5:00 PM ET Form 4
Insider Selling

MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer Sells $96K of Stock

Anatol Kreitzer, Chief Discovery Officer, sold 12,248 shares of MapLight Therapeutics, Inc. at $7.84 a share, worth $96K in total on Oct 15, 2026. Shares held after the trade: 168,678 (-6.8%).

Value
$96K
Shares
12,248
Price
$7.84
Role
Chief Discovery Officer
Holding change
-6.8%
Trade date
Oct 15, 2026
5:00 PM ET Form 4
Insider Selling

MapLight Therapeutics CMO Erin Pennock Foff Sells $124K of Stock

Erin Pennock Foff, CMO, sold 15,355 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $124K in total on Oct 15, 2026. Shares held after the trade: 296,906 (-4.9%).

Value
$124K
Shares
15,355
Price
$8.08
Role
CMO
Holding change
-4.9%
Trade date
Oct 15, 2026
5:00 PM ET Form 4
Insider Selling

MapLight Therapeutics General Counsel Kristopher Hanson Sells $72.9K of Stock

Kristopher Hanson, General Counsel, sold 9,020 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $72.9K in total on Oct 15, 2026. Shares held after the trade: 128,024 (-6.6%).

Value
$72.9K
Shares
9,020
Price
$8.08
Role
General Counsel
Holding change
-6.6%
Trade date
Oct 15, 2026
5:00 PM ET Form 4
Insider Selling

MapLight Therapeutics CAO and Interim CFO Jonathan Gillis Sells $82.1K of Stock

Jonathan Gillis, CAO and Interim CFO, sold 10,167 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $82.1K in total on Oct 15, 2026. Shares held after the trade: 142,315 (-6.7%).

Value
$82.1K
Shares
10,167
Price
$8.08
Role
CAO and Interim CFO
Holding change
-6.7%
Trade date
Oct 15, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.